1、.12.3.4.5.孙燕主编.内科肿瘤学.人民卫生出版社.2001,3,6636.7.适应症适应症肺癌肺癌(NSCLC&SCLC)NSCLC&SCLC)子宫颈癌子宫颈癌Cervical cancerCervical cancer卵巢癌卵巢癌Ovarian cancerOvarian cancer结直肠癌结直肠癌Colorectal cancerColorectal cancer胃癌胃癌Gastric cancerGastric cancer乳腺癌乳腺癌Breast cancerBreast cancer皮肤癌皮肤癌Skin cancerSkin cancer恶性淋巴瘤恶性淋巴瘤Malignan
2、t lymphomaMalignant lymphomaCAMPTOSAR结直肠癌结直肠癌正在申请:正在申请:Gastric cancerGastric cancer胃癌胃癌正在研究:正在研究:Stage II&III colon cancerStage II&III colon cancer辅助化疗;肺癌辅助化疗;肺癌8.张频等,国外医学肿瘤分册。1998;25(6):344346.9JCOG 9511JCOG 951110.11.12.Noda K,et al.N Eng J Med.2002;346(2):85-91Noda K,et al.N Eng J Med.2002;346(2)
3、:85-9113.Noda K,et al.N Eng J Med.2002;346(2):85-91Noda K,et al.N Eng J Med.2002;346(2):85-91CPT-11+DDPCPT-11+DDP方案疗效显著优于方案疗效显著优于VP16+DDPVP16+DDP14.100100 80 80 60 60 40 40 20 20 0 0CPT-11+DDPCPT-11+DDPVP16+DDPVP16+DDPP=0.002P=0.002月数月数总生存率()总生存率()0 12 24 36 0 12 24 36 60 60 Noda K,et al.N Eng J Med
4、.2002;346(2):85-91Noda K,et al.N Eng J Med.2002;346(2):85-91CPT-11+DDPCPT-11+DDP方案总生存率显著优于方案总生存率显著优于VP16+DDPVP16+DDP15.P=0.003P=0.003CPT-11+DDPCPT-11+DDPVP16+DDPVP16+DDP100100 80 80 60 60 40 40 20 20 0 00 12 24 36 0 12 24 36 60 60 月月无进展生存率()无进展生存率()Noda K,et al.N Eng J Med.2002;346(2):85-91Noda K,et
5、 al.N Eng J Med.2002;346(2):85-91CPT-11+DDPCPT-11+DDP方案无进展生存率显著优于方案无进展生存率显著优于VP16+DDPVP16+DDP16.Noda K,et al.N Eng J Med.2002;346(2):85-91Noda K,et al.N Eng J Med.2002;346(2):85-91发生率()发生率()CPT-11+DDPCPT-11+DDP方案安全性良好方案安全性良好CPT-11+DDPCPT-11+DDPVP16+DDPVP16+DDP17.Noda K,et al.N Eng J Med.2002;346(2):85-91Noda K,et al.N Eng J Med.2002;346(2):85-91